Quantcast

Latest Alpha-synuclein Stories

2014-07-31 12:29:21

AFFiRiS AG presents Phase I data on a first-of-its-kind treatment with support from The Michael J. Fox Foundation NEW YORK and VIENNA, July 31, 2014 /PRNewswire/ -- AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising Parkinson's drug target, to enter clinical testing. The Michael J. Fox...

2014-05-22 08:31:13

--Research Includes Stem Cells, Imaging and Exercise for Cognition-- MIAMI, May 22, 2014 /PRNewswire-USNewswire/ -- The National Parkinson Foundation (NPF) announced today that it has funded four new grants in Parkinson's disease (PD) research. The four grants target key scientific questions about how Parkinson's develops and how to optimize treatment. "NPF is propelling the most potentially transformative research forward," said Joyce Oberdorf, NPF's President and CEO. "This...

2014-04-28 08:33:12

EU support boosts development of therapeutic vaccines against Parkinson's and Multiple System Atrophy. AFFiRiS leads consortium. VIENNA, April 28, 2014 /PRNewswire/ -- An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem strategy to advance...

2014-04-23 16:29:24

NEW YORK, April 23, 2014 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) is launching a new funding program to promote collaborative analysis of subtypes of the protein alpha-synuclein. Aggregating in the cells of all people with Parkinson's disease (PD), alpha-synuclein is a major target for drug development. To advance those efforts, scientists must analyze different species of this protein -- resulting from splicing or post-translational...

2014-03-21 23:25:53

As part of its $219,000 initial multiple system atrophy research grant funding round, The MSA Coalition® has awarded $25,00 to Dr. Roy Freeman of Beth Israel Deaconess Medical Center for research to determine whether alpha-synuclein deposits are a valid biomarker for multiple system atrophy. Boston, MA (PRWEB) March 21, 2014 The Multiple System Atrophy Coalition has awarded a $25,000 grant to Dr. Roy Freeman of Beth Israel Deaconess Medical Center to carry out a pilot study to...

2014-03-18 23:29:58

The MSA Coalition announced in January 2014 the funding of five MSA research grants for a total of $219,000 including the project "Peripheral delivery of brain-targeted neurosin as a novel treatment for MSA". This pre-clinical proof-of-concept study in mice is being led by Eliezer Masliah, M.D. (University of California San Diego). San Diego, CA (PRWEB) March 18, 2014 The Multiple System Atrophy Coalition has awarded a $50,000 grant to Dr. Eliezer Masliah of the University of...

2014-02-25 08:33:01

NEW YORK, Feb. 25, 2014 /PRNewswire-USNewswire/ -- The Parkinson's Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF), is expanding to study individuals with genetic mutations associated with Parkinson's disease (PD). Researchers hope that greater understanding of the biology and clinical features of these participants -- people with or at risk to develop Parkinson's -- will lead to...

2014-01-08 17:05:18

Gladstone findings challenge conventional wisdom; point to new therapeutic strategies The most devastating aspect of Parkinson's disease may not be its debilitating symptoms, which rob its victims of their ability to control their own movement. It may not be the millions around the world and their families who suffer each day from the disease's harmful effects. Instead, it may in fact be that its root causes remain largely a mystery. But now, scientists at the Gladstone Institutes have...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related